Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause

Background Outcomes and treatment effects of therapy may vary according to the cause of heart failure (HF). Methods and Results In this post hoc analysis of the EMPEROR‐Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction) trial, the effect of em...

Full description

Bibliographic Details
Main Authors: Muhammad Shahzeb Khan, Javed Butler, Stefan D. Anker, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, James L. Januzzi, Ileana L. Piña, Michael Böhm, Piotr Ponikowski, Subodh Verma, Martina Brueckmann, Ola Vedin, Cordula Zeller, Faiez Zannad, Milton Packer
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
empagliflozin
heart failure
ischemic cause
reduced ejection fraction
sodium‐glucose co‐transporter‐2
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.027652

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.122.027652

Similar Items